Constipation usually means infrequent bowel movements, hard stools, straining, or a sense of incomplete evacuation, Rome IV defines functional constipation by symptom duration and frequency thresholds, not by a microbiome score. A stool report that flags low Bifidobacterium, “slow transit” on a vendor index, or Methanobrevibacter does not tell you whether the bottleneck is colonic transit, pelvic floor outlet dysfunction, medication effect, or insufficient fibre and fluid, and those pathways need different workups.
This page is a routing guide: use stool pattern, evacuation symptoms, and medications first; use Foundations for mechanism depth; treat taxa lists as secondary context.
Before anything else, red flags
Seek medical assessment promptly (do not rely on a microbiome test) if you have:
- Unintentional weight loss
- Rectal bleeding or black stools
- Anaemia or iron deficiency without explanation
- Persistent or worsening pain with fever
- New constipation after age 50 without prior evaluation
- Family history of colorectal cancer or inflammatory bowel disease with compatible symptoms
See Red flags, when to seek clinical care first.
Slow transit vs outlet dysfunction, the split a stool test cannot make
| Pattern | What you notice | Typical mechanisms | Tests that actually address it |
|---|---|---|---|
| Slow colonic transit | Infrequent urges, hard stools throughout, bloating that builds through the day | Reduced propulsion, methane-associated slowing (research), low fibre/fluid, some medications | Transit study (wireless marker, scintigraphy), breath methane in selected cases |
| Outlet / pelvic floor dyssynergia | Straining, feeling of blockage, need to splint, soft stool still difficult to pass | Paradoxical contraction of pelvic floor during evacuation | Anorectal manometry, balloon expulsion test, specialist biofeedback |
| Mixed | Both infrequent hard stools and difficult evacuation | Common in chronic constipation clinics | Often both transit and pelvic floor assessment |
Stool microbiome panels sample the colon and cannot measure pelvic floor coordination or whole-gut transit time directly. Vendor “transit scores” are proprietary and not interchangeable with validated transit tests.
Mechanism depth: Gut motility, Methane and colonic gas.
Decision tree, start with pattern, not taxa
Work through branches in order. More than one can apply.
Step 1, How do you evacuate?
| Pattern | Think about | Read next |
|---|---|---|
| Hard, infrequent stools, little straining at the anus | Slow transit, low fibre/fluid, hypothyroidism, opioids | Dietary fiber, Gut motility, medication review below |
| Straining, incomplete emptying, soft stool still stuck | Outlet dysfunction, rectocele (structural, clinical) | Pelvic floor referral; not fixable by probiotics alone |
| Bloating + constipation, upper symptoms after meals | SIBO/IMO overlap possible | SIBO & breath testing |
| Sudden change after new medication | Drug-induced constipation | Medications and microbiome |
| Long-standing IBS pattern, pain related to defecation | IBS-C subtype | IBS subtypes |
Step 2, Methane / IBS-C pattern
Methane on hydrogen/methane breath tests associates with slowed colonic transit in many studies, particularly constipation-predominant IBS. Intestinal methanogen overgrowth (IMO) is the term used when archaea such as Methanobrevibacter smithii dominate small-bowel or breath methane production in that context.
| Signal | What it does / does not mean |
|---|---|
| Positive methane breath test | Supports IMO/slow-transit hypothesis, treatment is clinical (diet, prokinetics, antimicrobials in selected cases) |
| Methanobrevibacter on stool report | Colonic detection; not equivalent to breath IMO, see Methanobrevibacter species page |
| Low diversity on panel | Non-specific; does not prove methane physiology |
Cross-links: Chronic bloating (lower abdominal distension + constipation), SIBO page.
Step 3, Low fibre vs low-FODMAP conflict
Reports often recommend more prebiotic fibre while symptom pages recommend lower fermentable load, both can be true at different stages.
| Situation | Practical sequence (with clinician/dietitian when possible) |
|---|---|
| Active bloating and pain with constipation | Identify FODMAP triggers or reduce fermentable load first, see FODMAPs |
| Stable symptoms, hard stools, low fibre intake | Titrate soluble fibre (e.g. psyllium) with adequate fluid, see Dietary fiber, Fiber supplements |
| Report says “increase inulin/FOS” but symptoms flare | FODMAP overlap; inulin is high-FODMAP for many IBS patients |
Insoluble wheat bran helps some people and worsens bloating in others, fibre type matters more than a generic “increase fibre” report line.
Step 4, Medication-induced
Common offenders: opioids, anticholinergics, iron supplements, calcium channel blockers, some antidepressants, aluminium antacids. Proton pump inhibitors alter small-bowel ecology in some studies but constipation is not universal.
Stopping or switching medication requires prescriber involvement. A microbiome test does not identify which drug is causal.
Evidence-tier table, what to try first (framing, not prescription)
Order depends on history, alarms, and prior trials.
| Approach | Evidence tier (constipation context) | Notes |
|---|---|---|
| Treat alarm features / exclude organic disease | Strong (clinical standard) | Red flags |
| Soluble fibre (psyllium) + fluids + activity | Strong for chronic constipation in guidelines | Titrate slowly if bloating coexists |
| Pelvic floor biofeedback when dyssynergia documented | Strong in specialist trials for outlet dysfunction | Requires diagnosis, not report inference |
| Osmotic laxatives (PEG, magnesium, as appropriate) | Strong symptomatic relief | Clinical choice by age, renal function, pregnancy |
| Stimulant laxatives (short-term or intermittent use) | Moderate | Long-term patterns need clinical follow-up |
| Low-FODMAP or portion control if bloating dominates | Strong in IBS RCTs for symptom bundles | See Low-FODMAP intervention |
| Hydrogen/methane breath testing when IMO/SIBO suspected | Conditional / debated | Stool kit ≠ breath test |
| Probiotics for constipation | Weak / strain-specific | Some strains show benefit in selected trials; genus on report ≠ product evidence |
| Stool microbiome test to choose treatment | Low | See below |
Guideline context: ACG chronic constipation emphasises pathophysiology-based treatment after appropriate evaluation.
Which tests help when
| Clinical question | Test | Stool microbiome panel? |
|---|---|---|
| Is there intestinal inflammation? | Fecal calprotectin | No, see Calprotectin |
| Is transit slow vs outlet blocked? | Transit marker study; anorectal manometry | No |
| Is methane / IMO contributing? | Hydrogen/methane breath test (protocol-sensitive) | Stool methanogen reads are indirect |
| Is coeliac disease possible? | Serology (with alarms or compatible history) | No |
| What ecology changed after antibiotics? | Repeat sequencing (same lab/method) | Optional trend context only, Post-antibiotic recovery |
What a stool microbiome report cannot answer
| Question | Can stool sequencing answer it? |
|---|---|
| Do I have pelvic floor dyssynergia? | No |
| Is my transit objectively slow? | No (vendor scores unvalidated for this) |
| Do I have IMO? | No, breath testing is separate |
| Should I start this probiotic strain? | No |
| Is constipation from low Bifidobacterium? | No, association in cohorts, not causal diagnosis |
Reports may show methanogen reads, low diversity, or “beneficial bacteria” deficits, all non-specific alone. Use Reading your microbiome report and Multi-marker synthesis if you have a full panel.